Login to Your Account

Analyst Likes Large-Cap Stocks As Safest Haven In Biotechnology

By Randall Osborne

Monday, May 20, 2002
With both sides still out for blood in the battle over their respective anti-anemia erythropoietin products, Transkaryotic Therapies Inc. (which won European approval in March for Dynepo) and Amgen Inc. (guarding the franchise it has, through the blockbuster Epogen) matched lawyers two weeks ago in an appeals hearing that offered few revelations. (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription